Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.2052W HIGH $7.95
Volume
275.54 K
Value Traded
1.56 M
Short % Float
8.75%
-4.4%Week
-13.24%1 Month
-0.24%3 Month
-2.13%6 Month
-66.9%5 Year
-70.36%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
254.30 M
EPS (TTM)
-0.46
P/E Ratio
-
Ent. Value
241.08 M
Total Shares
61.57 M
Float Shares
38.22 M
Insiders
37.93%
Institutions
35.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TLSI Catalyst Timeline
Dated clinical, regulatory and corporate events for TriSalus Life Sciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for TriSalus Life Sciences, Inc.
113Total events
6Upcoming
19Tier-1 (high impact)
2020 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲FDA ApprovalFDA Decision
FDA 510(k) clearance for TriNav Advance PEDD device
liver embolizationsource ↗
▲Reimbursement / PricingPost-Market
CMS establishes G-code extending reimbursement for vascular embolization procedures using pressure-generating catheter
◆Oral PresentationPresentation
Virtual KOL event featuring new real-world evidence for Pressure-Enabled Drug Delivery in liver cancer
liver cancersource ↗
●R&D DayPresentation
Hosted virtual KOL event discussing new real-world evidence for PEDD in liver cancer
liver cancersource ↗
●PublicationPresentation
Submitted for publication data from PEDIR study evaluating tumor-to-normal ratio in HCC and hypovascular tumors
hepatocellular carcinoma and hypovascular tumorssource ↗
▲PublicationPresentation
Real-world PEDD study published in Journal of Comparative Effectiveness Research
liver tumorssource ↗
▲Trial InitiationTrial
Launch of PREDICTT clinical trial evaluating Pressure-Enabled Drug Delivery in liver tumors
liver tumorssource ↗
◆Oral PresentationPresentation
Novel Approaches to Uterine Artery Embolization: A Clinical Assessment of Safety and Efficacy Using a Pressure Enabled Drug Delivery Device
Uterine fibroidssource ↗
◆Poster PresentationPresentation
Pressure Enabled Drug Delivery During Delivery of Embolic Spheres Enhances Hepatic Tumor Penetration in an Oncopig Model
Hepatic tumorssource ↗
◆Oral PresentationPresentation
Embolization of Neuroendocrine Tumor Metastases to the Liver: A Single-Center Experience Before and After the Introduction of Pressure Enabled Drug Delivery
Neuroendocrine tumor metastases to the liversource ↗
▼Equity OfferingCorporate
Pricing of $40.0 million public offering of 9,756,100 shares at $4.10 per share
▲Full ResultsPEDDClinical Data
Landmark real-world PEDD Study published: 603 PEDD patients vs 16,210 non-PEDD
liver cancersource ↗
●Oral PresentationPEDDPresentation
New clinical and preclinical PEDD data presented at 2026 SIR Annual Scientific Meeting
oncology and embolizationsource ↗
▼Equity OfferingCorporate
Raised $46.0 million in gross proceeds from equity offering in Q1 2026
◆Timing GuidancePresentation
Special meeting of stockholders to approve amendment to Certificate of Designations
◆Timing GuidancenelitolimodPresentation
Anticipates data from PERIO-03 Phase 1 study in mid-2025
locally advanced pancreatic cancersource ↗
▼Equity OfferingCorporate
Private placement of 5,500,000 shares at $4.00 per share for $22.0 million gross proceeds
▲Quarterly UpdateCorporate
Preliminary Q1 2025 revenue of approximately $9.2 million, 42% growth vs Q1 2024
◆Timing GuidancePresentation
Launch of exchange offer for Series A Convertible Preferred Stock
▲Timing GuidancePresentation
Provided 2025 guidance: >50% sales growth, >20% OpEx reduction, positive EBITDA, positive cash flow in H2 2025
●Runway Guidance UpdateCorporate
Cash runway through end of 2024 with current cash and $25M draw
▲Product LaunchPost-Market
Launched TriNav LV Infusion System and TriGuide Guiding Catheter for larger vessels
larger vessels in liver embolizationsource ↗
▲Trial InitiationTrial
Initiated PROTECT registry trial for multinodular goiter using TriNav system
multinodular goitersource ↗
▲Oral PresentationnelitolimodPresentation
Presented positive Phase 1 data from PERIO-01 trial at SITC meeting
uveal melanoma with liver metastases (UM-LM)source ↗
▲Enrollment CompletenelitolimodTrial
Completed enrollment in Phase 1 dose escalation study PERIO-01 in UM-LM
uveal melanoma with liver metastases (UM-LM)source ↗
◆Oral PresentationnelitolimodPresentation
Final Phase 1 data presentation for locally advanced pancreatic cancer
locally advanced pancreatic cancersource ↗
▲Enrollment MilestonenelitolimodTrial
Treated 100 patients across four indications and three clinical trials
liver and pancreatic tumorssource ↗
▲Debt Royalty FinancingCorporate
Closed debt financing facility with OrbiMed for up to $50 million
▲Enrollment CompletenelitolimodTrial
Completed enrollment in multiple Phase 1 trials (100 patients) for nelitolimod via PEDD
uveal melanoma liver metastases, hepatocellular cancer, intrahepatic cholangiocarcinomasource ↗
▲RWE DataTriNavClinical Data
Publication of real-world study in Current Medical Research and Opinion on TriNav for TACE/TARE
hepatocellular carcinoma and liver metastasessource ↗
Past FDA Catalysts and PDUFA Decisions
How TLSI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-06-30 | SD-101 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$35M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 88%
Micro Cap(rank 579 of 658)
Percentile Rank
TriSalus Life Sciences, Inc. faces pipeline headwinds (23/100), with $368M risk-adjusted pipeline value, led by SD-101 in Prostatic Neoplasms (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SD-101 Small moleculeCompletedNCT03007732 | Prostatic Neoplasms | Phase 2 | COMPLETED | 23 | Mar 31, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every TLSI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SD-101 | uveal melanoma liver metastases | Phase 1 | 2023-06-12 | treatment related serious adverse event rate: 5%; patients enrolled: 39; treatment naive patients: 5; patients failed prior therapy: 81%; stable disease patients: 15; partial response patients: 1; ct DNA decrease patients: 8; evaluable patients: 13Read More | TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting New datRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Stevens JenniferOfficer (Chief Regulatory Officer) | Sell | -316 123,794 held | $4.39 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TLSI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TLSI for Q2 2026. | ||||
TLSI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TLSI ranks across every disease it competes in
Competitive Position is a premium feature
See how TLSI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTLSI News
TLSITriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
TriSalus Life Sciences has received FDA 510(k) clearance for TriNav® Advance, enhancing its Pressure-Enabled Drug Delivery™ (PEDD™) portfolio. This new device aims to improve treatment delivery for patients with solid tumors, integrating advanced technology with existing therapies. The clearance marks a significant step in TriSalus's commitment to oncology innovation.
Read more →TLSITriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TriSalus Life Sciences will participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference. This event is significant for the company as it allows them to engage with investors and showcase their developments. Participation in such conferences can enhance their visibility in the biopharma sector.
Read more →TLSI▲ +15.2%on this news
TriSalus Life Sciences Reports Second Quarter 2026 Results
TriSalus Life Sciences reported its financial results for Q2 2026, highlighting significant year-over-year and sequential growth. The company is focused on integrating novel delivery technologies with standard therapies to improve treatment for solid tumors. This operational update reflects the company's commitment to advancing oncology care.
Read more →TLSITriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
TriSalus Life Sciences will participate in the Canaccord Genuity 46th Annual Growth Conference, featuring CEO Mary Szela and CFO David Patience. The event will include one-on-one meetings, highlighting the company's commitment to oncology and investor engagement. This participation reflects the company's ongoing efforts to enhance its visibility in the biopharma sector.
Read more →TLSITriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences, an oncology-focused company, has announced a conference call scheduled for August 6, 2026. The call will discuss the financial results for the quarter ending June 30, 2026. This event highlights the company's commitment to transparency and investor engagement.
Read more →TLSI▲ +6.3%on this news· ran to +26% by day 3
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
TriSalus Life Sciences is set to host a virtual Key Opinion Leader (KOL) event on June 24. The event will showcase new real-world evidence regarding their Pressure-Enabled Drug Delivery™ technology specifically for liver cancer treatment. This initiative highlights the company's commitment to advancing therapeutic options in oncology.
Read more →TLSIReal-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
The article discusses a real-world study published in the Journal of Comparative Effectiveness Research that highlights improved clinical outcomes and charge avoidance related to PEDD. However, specific details about the study's findings or implications are not provided in the text.
Read more →TLSITriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
TriSalus Life Sciences has reported its first quarter 2026 results, highlighting both commercial and clinical advancements aimed at fostering long-term growth. The report indicates the company's ongoing efforts to enhance its market position and clinical outcomes. However, specific details regarding financial performance or clinical data were not disclosed in the article.
Read more →TLSITriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
TriSalus Life Sciences has announced the launch of the PREDICTT clinical trial, which aims to evaluate a novel pressure-enabled drug delivery system for treating liver tumors. This innovative approach could enhance the effectiveness of therapies for patients with this challenging condition. The trial represents a significant step forward in cancer treatment methodologies.
Read more →TLSITriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences will host a conference call on May 12, 2026, to discuss its financial results for Q1 2026. The company focuses on integrating novel delivery technology with standard therapies for solid tumors. Their investigational immunotherapeutic, nelitolimod, aims to enhance treatment outcomes by addressing immunosuppressive environments. A press release will precede the call.
Read more →TLSITriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
TriSalus Life Sciences will present new data at the Society of Interventional Radiology Annual Scientific Meeting in April 2026. The company will showcase its Pressure Enabled Drug Delivery platform, which aims to enhance therapeutic delivery for solid tumors. Presentations will include findings on hepatic tumor penetration and uterine artery embolization. The data supports the potential of PEDD in improving treatment outcomes.
Read more →TLSITriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
TriSalus Life Sciences has announced the appointment of Richard Marshall, M.D., as their new Chief Medical Officer. This strategic move is expected to enhance the company's leadership team. Further details regarding his previous experience and future plans at TriSalus were not disclosed in the announcement.
Read more →TLSITriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
TriSalus Life Sciences will host a conference call on March 5, 2026, to discuss its financial results for Q4 2025. The call will provide insights into the company's performance and future plans, including its innovative drug delivery technologies and investigational immunotherapeutic, nelitolimod. A press release will precede the call, and a replay will be available afterward.
Read more →TLSI▲ +18.2%on this news
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
TriSalus Life Sciences has announced the pricing of its public offering, selling 9,756,100 shares at $4.10 each, aiming to raise approximately $40 million. The offering is expected to close around February 23, 2026, pending customary closing conditions. Lake Street Capital Markets is the sole book-runner for this offering.
Read more →TLSITriSalus Life Sciences Proposes Public Offering
TriSalus Life Sciences, an oncology-focused medical technology company, announced its intent to conduct an underwritten public offering of its common stock. The offering entails all shares being sold by the company, with underwriters receiving an option for additional shares. The final terms of the offering will be disclosed in a prospectus supplement to be filed with the SEC. Various aspects of the public offering and TriSalus's future potential treatments are discussed in light of market conditions and regulatory compliance.
Read more →TLSITriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
TriSalus Life Sciences has appointed Michael Stansky to its Board of Directors, effective February 4, 2026, following the resignation of Dr. Arjun Desai. Stansky brings 40 years of experience in investment management and healthcare, which the company believes will support its strategic growth objectives. The board expressed gratitude for Desai's contributions during his tenure.
Read more →TLSITriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
TriSalus Life Sciences has successfully completed its exchange offer for Series A Convertible Preferred Stock, with nearly 99% of shares tendered in the process. The exchange allows holders to convert their preferred shares into common stock at a ratio of 3.3 shares. The SEC's effective declaration of the registration statement facilitates this transition, which is expected to be finalized by August 1, 2025. The initiative highlights the company's ongoing focus on oncology advancements and improving patient outcomes.
Read more →TLSI▼ -8.8%on this news
TriSalus Life Sciences Announces Chief Financial Officer Transition with Appointment of David B. Patience
TriSalus Life Sciences has announced the appointment of David B. Patience as Chief Financial Officer, effective July 1, 2025. He succeeds James E. Young, who stepped down for personal reasons. David Patience brings extensive experience from his previous role as CFO at Accelerate Diagnostics and has a strong background in strategic product planning and market analysis. The transition aims to maintain stability while leveraging Patience's financial leadership in the company's growth efforts.
Read more →TLSI▼ -10.3%on this news
TriSalus Life Sciences Announces $22.0 Million Preliminary Q1 2025 Unaudited Financial Results
TriSalus Life Sciences has announced a private placement of $22 million, aimed at accelerating current and future applications of its cancer treatment technologies. Preliminary financial results for Q1 2025 indicate a revenue of approximately $9.2 million, reflecting a 42% growth compared to Q1 2024. The company plans to simplify its capital structure through an exchange offer for its Series A Convertible Preferred Stock, which is expected to enhance operational efficiency. The funds raised will be utilized for working capital and corporate purposes, as the company continues to advance its innovative therapies for solid tumors.
Read more →About TriSalus Life Sciences, Inc.
Headquarters6272 WEST 91ST AVENUE, WESTMINSTER, CO, 80031
BIOPHARMAWATCH ELITE PLUS
Trade the next TLSI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime